Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit. - Seite 2

The summit itself provides an essential forum for stakeholders, primarily across Spanish and Portuguese markets to engage with these innovations and consider their application in a field that is increasingly reliant on AI to streamline processes. These innovationsenhance research methodologies, and ultimately, deliver cost-effective solutions and profitability in the fast-evolving landscape of biotechnology. Within this dynamic context, Dr. Trieu will illuminate how Oncotelic's chatbot technology, with its advanced capabilities, is designed to align with these broader trends. Dr. Trieu's presentation will underscore the potential of conversational AI to not just inform but also transform the biotech industry across language barriers.

About The Ibero-American Chatbot and Conversational AI Summit

The Ibero-American Chatbot and Conversational AI Summit is a distinguished online event scheduled for November 29th-30th, 2023. It serves as a pivotal gathering for pioneering thinkers, researchers, and business leaders who are at the forefront of conversational AI, particularly within the Spanish and Portuguese-speaking communities. Over two days, the summit will explore a myriad of topics, including the latest trends, innovations, policies, and regulatory developments that are shaping the future of AI in conversations.

This conference is uniquely tailored to facilitate in-depth discussions on how conversational AI can be strategically utilized to streamline business operations, augment research capabilities, and enhance profitability. Through a blend of keynote speeches, case studies from leading brands, and interactive sessions, attendees will have the chance to glean valuable insights from experts across various regions.

With a commitment to inclusivity and knowledge-sharing, the summit offers complimentary registration, making it an accessible and valuable networking hub for professionals eager to delve into the cutting-edge of conversational AI technology. To learn more and participate in this transformative event, please visit the official event website.

About Oncotelic

Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023.